Search Results for 'hcv peg'

hcv peg published presentations and documents on DocSlides.

PEG alfa-2a RBV versus

PEG alfa-2a RBV versus

by alexa-scheidler

. PEG alfa-. 2a . versus. INF RBV . APRICOT S...

by tawny-fly

RBV . versus. . PEG alfa-. 2a . versus. INF + R...

Future HCV Treatment Paradigms

Future HCV Treatment Paradigms

by kittie-lecroy

Mark Sulkowski, MD . Professor of Medicine. Medic...

HIV-HCV Coinfection in the era of effective antiviral therapy

HIV-HCV Coinfection in the era of effective antiviral therapy

by mia

Mark Sulkowski, . MD. Professor of Medicine. Medic...

Management of HCV in Co-Infected Patients

Management of HCV in Co-Infected Patients

by danika-pritchard

Marie-Louise Vachon, MD, . MSc. Division of . Inf...

by alida-meadow

versus . Telaprevir. . with PR in GT1 . ATTAIN ...

by aaron

with PEG + RBV in Genotype 1. SPRINT. -1. Phase ....

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

by cheryl-pisano

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

Updates in Treatment of Hepatitis C

Updates in Treatment of Hepatitis C

by myesha-ticknor

Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...

Peginterferon alfa-2a (

Peginterferon alfa-2a (

by tatyana-admore

Pegasys. ). Prepared by: David Spach, MD & H....

Boceprevir in Treatment Naive

Boceprevir in Treatment Naive

by min-jolicoeur

SPRINT-2. Phase 3, Treatment . Naive. Treatment. ...

Peginterferon alfa-2a +

Peginterferon alfa-2a +

by stefany-barnette

RBV . versus. Interferon alfa. -. 2a + RBV . ACT...

Global Hepatitis C Guidelines 2014: recommendations for a public health approach

Global Hepatitis C Guidelines 2014: recommendations for a public health approach

by olivia-moreira

Gottfried . Hirnschall. Background . HCV infectio...

Resistance to Direct Acting Antiviral Therapy

Resistance to Direct Acting Antiviral Therapy

by tawny-fly

Resistance to HCV DAAs: What is the threat level...

Hepatitis C: A New Era In Treatment And Cure

Hepatitis C: A New Era In Treatment And Cure

by myesha-ticknor

Adam . Deising. , DO. LCDR MC USN. Director of . ...

Hepatitis C Dr. Alipour

Hepatitis C Dr. Alipour

by beatrice

Chronic hepatitis C virus (HCV) infection is one o...

Boceprevir with PEG + RBV in Genotype 1

Boceprevir with PEG + RBV in Genotype 1

by caroline

SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. ...

Simeprevir in HIV Coinfection,

Simeprevir in HIV Coinfection,

by noah

GT-1. C212 Trial. Phase . 3. Treatment. Naïve an...

FISSION Design Objective

FISSION Design Objective

by travis

Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...

by ellena-manuel

Genotype . 1 . (. Viral . Relapsers. ). PROMISE ....

Hepatitis C Drug Pipeline

Hepatitis C Drug Pipeline

by cheryl-pisano

HCV WORLD CAB .  FEBRUARY 2014. BANGKOK, THAI...

Current strategies for the management of treatment naïve a

Current strategies for the management of treatment naïve a

by min-jolicoeur

Mark S. Sulkowski, MD. Medical Director, Viral He...

HIV and HCV Update for the Pharmacist – June 2014

HIV and HCV Update for the Pharmacist – June 2014

by marina-yarberry

John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. R...

Out With the Old and In With the New, Again?

Out With the Old and In With the New, Again?

by test

Out With the Old, In With the New. Current Standa...

David Fletcher, MD

David Fletcher, MD

by tatiana-dople

Department of Medicine. University of Toronto. Co...

Boceprevir in Treatment Experienced

Boceprevir in Treatment Experienced

by tatiana-dople

RESPOND-2. Phase . 3. Treatment. . Experienced. ...

Direct Acting Antivirals: What are they? What is their pl

Direct Acting Antivirals: What are they? What is their pl

by tawny-fly

Mark Sulkowski, MD. Associate Professor of Medici...

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2

by debby-jeon

. or 3 . LONESTAR-2. Phase 2. Treatment. . Exp...

by pasty-toler

Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...

How to optimize treatment of G1 patients?

How to optimize treatment of G1 patients?

by KissesForYou

Prof. G. K. K. Lau 2012. Standard of care (SOC) ...

NS5A and polymerase inhibitors

NS5A and polymerase inhibitors

by LoveBug

Mark Sulkowski, MD. Professor of Medicine. Johns H...

M.W. Fried , 1 M. Buti,

M.W. Fried , 1 M. Buti,

by iamamercy

2. G.J. Dore,. 3. P. Ferenci,. 4. . I. Jacobson...

Updated Guidelines for Managing HIV/HCV Co-Infection

Updated Guidelines for Managing HIV/HCV Co-Infection

by karlyn-bohler

John J . Faragon. , . PharmD. , BCPS, AAHIV-P. Re...

by aaron

W24. DCV + PR. Placebo + PR. Yes. Dore GJ. Gastro...

by myesha-ticknor

Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...

Are (exogenous) interferons

Are (exogenous) interferons

by amey

really necessary?. Peter . Ferenci. Medical Univer...

Practical management of PI therapy

Practical management of PI therapy

by TropicalParadise

in Hepatitis C . Paris . Februari. 2012. Ola . We...